CD4+CD25highFOXP3+ T regulatory cells as a biomarker of disease activity in systemic lupus erythematosus: A prospective study

Clinical and Experimental Rheumatology

Volumn 32, Issue 5, 2014, Pages 630-639

  Tselios, Konstantinos ^a   Sarantopoulos, Alexandros ^a   Gkougkourelas, Ioannis ^a   Boura, Panagiota ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Activity; Biomarkers; SLEDAI; Systemic lupus erythematosus; T regulatory cells

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL2RA PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CD4+ CD25 HIGH FOXP3+ REGULATORY T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PREDICTIVE VALUE; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; RELAPSE; RELIABILITY; REMISSION; SENSITIVITY AND SPECIFICITY; SLEDAI; STUDENT T TEST; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PROGNOSIS; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TIME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; YOUNG ADULT;

EID: 84907571219     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. TSOKOS GC: Systemic lupus erythematosus. N Eng J Med 2011; 365: 2110-21.
2. LIU CC, AHEARN JM: The search for lupus biomarkers. Best Pract Res Clin Rheumatol 2009; 23: 507-23.
3. ILLEI GG, TACKEY E, LAPTEVA L, LIPSKY PE: Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum 2004; 50: 2048-65.
4. CRISPIN JC, LIOSSIS SN, KIS-TOTH K et al.: Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010; 16: 47-57.
5. MUDD PA, TEAGUE BN, FARRIS AD: Regulatory T cells and systemic lupus erythematosus. Scand J Immunol 2006; 64: 211-8.
6. + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011; 10: 744-55.
7. SHEVACH EM: From vanilla to 28 flavours: multiple varieties of T regulatory cells. Immunity 2006; 25: 195-201.
8. + T cells. Cel Mol Immunol 2006; 3: 189-95.
9. MIYARA M, AMOURA Z, PARIZOT C et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005; 175: 8392-400.
10. high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178: 2579-88.
11. + regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007; 601: 113-9.
12. TAN EM, COHEN AS, FRIES JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
13. HOCHBERG MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
14. BOMBARDIER C, GLADMAN DD, UROWITZ MB, CARON D, CHANG CH: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
15. WEENING JJ, D'AGATI VD, SCHWARTZ MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-30.
16. MIYAKIS S, LOCKSHIN MD, ATSUMI T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Thromb Haemost 2006; 4: 295-306.
17. ILLEI GG, TACKEY E, LAPTEVA L, LIPSKY PE: Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004; 50: 1709-20.
18. PETRI M: Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis 2007; 66(Suppl 3): 361-364
19. BERTSIAS G, IOANNIDIS JPA, BOLETIS J et al.: EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195-205.
20. + T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus. Egypt J Immunol 2005; 12: 25-31.
21. +) regulatory T cells in patients with systemic lupus erythematosus. Lupus 2007; 16: 489-96.
22. YATES J, WHITTINGTON A, MITCHELL P, LECHLER RI, LIGHTSTONE L, LOMBARDI G: Natural regulatory T cells: numbers and function are normal in the majority of patients with lupus nephritis. Clin Exp Immunol 2008; 153: 44-55.
23. + T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 1037-40.
24. ALVARADO-SANCHEZ B, HERNANDEZ-CASTRO B, PORTALES-PEREZ D et al.: Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2006; 27: 110-8.
25. VARGAS-ROJAS MI, CRISPIN JC, RICHAUD-PATIN Y, ALCOCER-VARELA J: Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus 2008; 17: 289-94.
26. + regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids. Clin Immunol 2008; 127: 151-7.
27. LIN SC, CHEN KH, LIN CH, KUO CC, LING QD, CHAN CH: The quantitative analysis of peripheral blood FOXP3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients. Eur J Clin Invest 2007; 37: 987-96.
28. BONELLI M, SAVITSKAYA A, Von DALWIGK K et al.: Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus. Int Immunol 2008; 20: 861-8.
29. + regulatory T cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus. Immunology 2006; 117: 280-6.
30. KLECZYNSKA W, JAKIELA B, PLUTECKA H, MILEWSKI M, SANAK M, MUSIAL J: Imbalance between Th17 and regulatory T-cells in systemic lupus erythematosus. Folia Histochem Cytobiol 2011; 49: 646-53.
31. HU S, XIAO W, KONG F, KE D, QIN R, SU M: Regulatory T cells and their molecular markers in peripheral blood of patients with systemic lupus erythematosus. J Huazhong Univ Sci Technolog Med Sci 2008; 28: 549-52.
32. HABIBAGAHI M, HABIBAGAHI Z, JABER-IPOUR M, AGHDASHI A: Quantification of regulatory T cells in peripheral blood of patients with systemic lupus erythematosus. Rheumatol Int 2011; 31: 1219-25.
33. + regulatory T cells during repeated plasmapheresis treatment of patients. Autoimmunity 2007; 40: 521-8.
34. + regulatory T-cell subpopulations in systemic lupus erythematosus. Immunology 2009; 127: 196-205.
35. COOK RJ, GLADMAN DD, PERICAK D, UROWITZ MB: Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J Rheumatol 2000; 27: 1892-5.
36. + T cells are associated with immunological remission of lupus. J Immunol 2009; 183: 6346-58.
37. SFIKAKIS PP, SOULIOTIS VL, FRAGIADAKI KG, MOUTSOPOULOS HM, BOLETIS JN, THEOFILOPOULOS AN: Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007; 123: 66-73.
38. VIGNAS-PEREZ M, HERNANDEZ-CASTRO B, PAREDES-SAHAROPOULOS O et al.: Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83.
39. + Treg cells decrease in patients with lupus nephritis. Rheumatol Int 2012; 32: 949-58.
40. EDELBAUER M, KSHIRSAGAR S, RIEDL M et al.: Acivity of childhood lupus nephritis is linked to altered T cell and cytokine homeostasis. J Clin Immunol 2012; 32: 477-87.
41. + T regulatory cells for the assessment of disease activity in systemic lupus erythematosus. Lupus 2008; 17: 455 (abstract).
42. JADIDI-NIARAGH F, MIRSHAFIEY A: The deviated balance between regulatory T cell and Th17 in autoimmunity. Immuno-pharmacol Immunotoxicol 2012; 34: 727-39.